Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
НЦПЗ РАМН, клиника кардиологии ММА им. И.М.Сеченова
Список исп. литературыСкрыть список 1. Козырев В.Н., Смулевич А.Б., Дробижев М.Ю., Краева Г.К., Кубраков М.А. Психотропные средства, применяемые в психиатрическом стационаре (фармакоэпидемиологические аспекты) Журн. неврол. и психиатр. им. С.С. Корсакова 2003;103(11): 25–32. 2. Оганов Р.Г., Ольбинская Л.И., Смулевич А.Б., Дробижев М.Ю., Шальнова С.А., Погосова Г.В. Депрессии и расстройства депрессивного спектра в общемедицинской практике. Результаты программы КОМПАС. Кардиология 2004;1:48–54. 3. Смулевич А.Б., Сыpкин А.Л., Козыpев В.Н., Дpобижев М.Ю. Психофаpмакотеpапия и пpоблема оpганизации психиатpической помощи в соматическом стационаpе. Клин. медицина 2000; 10:22–8. 4. Смулевич А.Б. Депрессия при соматических и психических заболеваниях. М.: ООО “Медицинское информационное агентство”, 2003. 5. Stahl SM. Essential psychopharmacology of depression and bipolar disorder. Cambridge, Cambridge university press, 2000, 175P. 6. Pitsikas N. Duloxetine Eli Lilly and Co. Curr Opin Invest Drugs 2000:1:116–21. 7. Sauer H, Huppertz-Helmhold S, Dierkes W. Efficacy and safety of venlafaxine ER vs. amitriptyline ER in patients with major depression of moderate severity. Pharmacopsychiatry 2003 Sep;36(5):169–75. 8. Gasto C, Navarro V, Marcos T et al. Single-blind comparison of venlafaxine and nortriptyline in elderly major depression. J Clin Psychopharmacol. 2003 Feb;23(1):21–6. 9. Silverstone PH, Entsuah R, Hackett D. Two items on the Hamilton Depression rating scale are effective predictors of remission: comparison of selective serotonin reuptake inhibitors with the combined serotonin/norepinephrine reuptake inhibitor, venlafaxine. Int Clin Psychopharmacol 2002 Nov;17(6):273–80. 10. Saiz-Ruiz J, Ibanez A, Diaz-Marsa M et al. Efficacy of venlafaxine in major depression resistant to selective serotonin reuptake inhibitors. Prog Neuropsychopharmacol Biol Psychiatry 2002 Oct;26(6):1129–34. 11. Depont F, Rambelomanana S, Puil S. Le et al. Antidepressants: psychiatrists’ opinions and clinical practice. Acta Psychiatr Scand 2003:108:24–31. 12. Goldstein DJ, Mallinchrodt C, LuY, Demitrack MA. Duloxetine in the treatment of major depressive disorder: A double blind clinical trial. J Clin Psychiatry 2002;63:225–31. 13. Detke MJ, LuYili, Goldstein DJ et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002:63:308–15. 14. Norton P, Zinner NR, Yalcin I, Bump RC. Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecoi 2002:187:40–8. 15. Zinner N, Dmochowski R, Miklos J et al. Duloxetine versus placebo in the treatment of stress urinary incontinence (SUI) [abstract]. Neurourol Urodynam 2002:21:383–4. 16. Raskin J, Goldstein DJ, Mallinckrodt CH, Ferguson MB. Duloxetine in the Long-Term Treat-ment of Major Depressive Disorder. Pharm D J Clin Psychiatry 64:10, October 2003. 17. Справочник Видаль. Лекарственные препараты в России. М., 2004. 18. Anononims Venlafaxine: a new dimension in antidepressant pharmacotherapy. J Clin Psychiatry 1993 Mar;54(3):119–26. 19. Rechlin T. Effects of psychopharmacologic therapy on heart rate variation] Nervenarzt. 1995 Sep;66(9):678–85. 20. Cohen MC, Rohtla KM, Lavery CE et al. Meta-analysis of the morning excess of acute myocardial infarction and sudden cardiac death. Am J Cardiol 1997; 79: 1512–6. 21. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. 22. Jiang W, Krishnan RR, O'Connor CM. Depression and heart disease: evidence of a link, and its therapeutic implications. CNS Drugs 2002;16(2):111–27. 23. Stoudemire A, Moran MG, Fogel BS. Psychotropic drug use in the medically ill: Part I. Psychosomatics. 1990 Fall;31(4):377–91. 24. Liu B, Anderson G, Mittmann N et al. Use of selective serotonin_reuptake inhibitors of tricyclic antidepressants and risk of hip fractures in elderly people. Lancet 1998;351:1303_7. 25. Boyd IW. Hypertension with moclobemide. Lancet 1995 Dec 2;346(8988):1498. 26. Alter P, Tontsch D, Grimm W. Doxepin-induced torsade de pointes tachycardia. Ann Intern Med 2001 Sep 4;135(5):384–5.